Monivent AB (XSAT:MONI) Growth Rank: 3 (As of Sep. 17, 2026) — 40% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:MONI Monivent AB XSAT:MONI
27 GF Score
Price kr0.17
GF Value kr0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Monivent AB Growth Rank?

Monivent AB XSAT:MONI 27 Growth Rank is 3 as of Sep. 17, 2026, which is 40% below its 10-year median of 5.00. GuruFocus rates XSAT:MONI with a GF Score™ of 27/100 and a GF Value™ of kr0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Monivent AB has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

XSAT:MONI vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Monivent AB's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monivent AB Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Monivent AB's Growth Rank distribution charts can be found below:

* The bar in red indicates where Monivent AB's Growth Rank falls into.


XSAT:MONI
27GF Score
Monivent AB XSAT:MONI
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 3 mean?
Monivent AB (XSAT:MONI) has a Growth Rank of 3 as of Sep. 17, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Monivent AB and its competitors. This is 40% below median its historical median of 5.00. Over the past decade, Monivent AB's Growth Rank has ranged from 1.00 to 8.00.
Is Monivent AB's Growth Rank too high?
Monivent AB's current Growth Rank of 3 is 40% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. Overall, Monivent AB has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monivent AB's Growth Rank compare to ABT and SYK?
Monivent AB's Growth Rank of 3 can be compared against companies in the Medical Devices & Instruments industry. Historically, Monivent AB's own Growth Rank has ranged from 1.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Monivent AB and its competitors. Monivent AB's current Growth Rank is 3, which is 40% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monivent AB stock overvalued right now?
Based on GuruFocus' analysis, Monivent AB (XSAT:MONI) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.17 — trading 236% above its estimated fair value. The current Growth Rank is 3, which is 40% below median its 10-year median of 5.00. Monivent AB's overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Monivent AB (XSAT:MONI), the current Growth Rank is 3 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Monivent AB (XSAT:MONI) Overvalued in 2026?

Based on GuruFocus' analysis, Monivent AB stock appears to be overvalued. The current stock price of kr0.17 is trading 236% above its estimated GF Value™ of kr0.05. GuruFocus considers Monivent AB to be Significantly Overvalued.

Key valuation signals for XSAT:MONI:

  • Growth Rank: 3 (40% below median its 10-year median of 5.00)
  • GF Value™: kr0.05 vs. price of kr0.17 (236% above fair value)
  • GF Score™: 27/100 with 5 warning signs

No single metric tells the full story. See the XSAT:MONI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Monivent AB Business Description

Address Regnbagsgatan 8B, Gothenburg, SWE, SE-417 55
Monivent AB is a medtech company focused on improving the care given to newborn babies in need of respiratory support at birth. The company has developed a patented solution that provides continuous feedback on the volumes of air given to the newborn during manual ventilation. The airflow is measured directly in the face mask and feedback on the ventilation parameters is displayed numerically and graphically in real-time on the external monitor. The company's product is Monivent Neo100.
27GF Score

Get the complete analysis for XSAT:MONI

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.17
Price
kr0.05
GF Value